ArticleScientific reports2026
Phytochemical composition and bioactivities of Saudi endemic Reseda pentagyna essential oils.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Reseda pentagyna, a medicinal plant native to Saudi Arabia, has little scientific evidence of its phytochemical composition and biological capabilities. Despite its potential therapeutic benefits, the Resedaceae family has received little research attention. The purpose of this study was to analyze the phytochemical composition of R. pentagyna leaves essential oil (RPLEO) from Abha, Saudi Arabia, and evaluate its antioxidant, antibacterial, antidiabetic, and cytotoxic effects. The essential oils (EOs) were extracted via hydro-distillation and yielded 4.75 ± 1.75 (W/V). GC-MS analysis showed a robustly dominated monoterpenoid composition, mainly carvacrol (21.59%) as the predominant compound, followed by thymol (3.62%) and other phenolic constituents. RPLEO exhibits high antioxidant activity (DPPH IC50 = 80.13 ± 1.53 µg/mL, ABTS IC50 = 92.72 ± 1.34 µg/mL), which explains the high TPC (141.30 mg GAE/g) and TFC (88.34 mg QAE/g). Furthermore, RPLEO showed an antibacterial activity against Gram-negative pathogens (MIC = 6.25–12.50 µg/mL). It also showed notable antidiabetic potential by inhibiting α-amylase (IC50 = 82.31 µg/mL) and α-glucosidase (IC50 = 87.49 µg/mL) enzymes. Furthermore, it induced considerable cytotoxicity against HepG2 (IC50 = 112.34 µg/mL) and MCF-7 (IC50 = 126.34 µg/mL) cells, confirmed by the upregulation of pro-apoptotic markers (caspase-3, -8, -9, Bax) and downregulation of anti-apoptotic markers (Bcl-2, Bcl-xL). This study provides the first comprehensive analysis of RPLEO, demonstrating significant bioactivity. Further investigations, including compound isolation, in vivo validation, and clinical translation, are recommended to fully realize its medicinal potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.